If you have been diagnosed with metastatic non-small cell lung cancer , you may be eligible to take part in a new international clinical trial.
 
At HC Cancer Centre, we are running a phase III clinical trial for patients whose tumours show high PD-L1 expression. Our team assesses each case on an individual basis, supports the patient throughout the process and clearly explains whether they are likely to benefit from this treatment option.

What does this study involve?

The study compares ivonescimab with pembrolizumab as a first-line treatment. Its aim is to assess whether ivonescimab can improve treatment outcomes and offer a new treatment option to these patients.

Who can take part?

• Men and women aged 18 or over.
• Patients diagnosed with metastatic stage IV non-small cell lung cancer.
• Positive PD-L1 expression (our team will help you confirm whether this is the case).

Cost

Taking part in this trial does not involve any cost to the patient. All medical procedures are covered by the study sponsor.

Benefits of taking part

• Access to an innovative treatment under specialised medical supervision
• Personalised medical care throughout the trial.
• Contribute to advancing research into lung cancer.